Namandje Bumpus

CIK: 0002060594

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RXRX

RECURSION PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 18, 2026
Sale(S)
Direct
4K shares at avg. $3.18$13K
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 17, 2026
Award(A)
Direct
88.4K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 3, 2026
Sale(S)
Direct
4.4K shares at avg. $3.54$16K
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Direct
11K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Mar 17, 2025
Award(A)
Direct
36.5K shares-

		Type	Shares	Price		Ownership
Jun 18, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Sale(S)	3,963	$3.18	$12,602	Direct
Jun 17, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	88,424	-	$0	Direct
Jun 3, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Sale(S)	4,386	$3.54	$15,526	Direct
Jun 18, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	11,008	-	-	Direct
Mar 17, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	36,549	-	-	Direct

1-5 of 5 transactions

About Bumpus Namandje

Bumpus Namandje (SEC CIK 0002060594) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX).

Signal8 holds 5 ownership filings by Bumpus Namandje (1 Form 3, 4 Form 4), filed between Mar 19, 2025 and Jun 22, 2026. Those filings report 5 transactions, from Mar 17, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bumpus Namandje's filings is in SALT LAKE CITY, UT.

Recent filings by Bumpus Namandje

Jun 18, 2026: Open-market sale of RXRX shares (Form 4, code S).
Jun 17, 2026: Grant or award of RXRX shares (Form 4, code A).
Jun 3, 2026: Open-market sale of RXRX shares (Form 4, code S).
Jun 18, 2025: Grant or award of RXRX shares (Form 4, code A).
Mar 17, 2025: Grant or award of RXRX shares (Form 4, code A).

Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)

Borgeson Blake, Director
HERSHBERG ROBERT, Director
Dar Zavain, Director
Li Dean Y, Director
Taylor Ben R, Chief Financial Officer
Khan Najat, CEO and President

How to read Form 4 transaction codes